Goodwin Biotechnology, Inc.
31 articles about Goodwin Biotechnology, Inc.
-
Powerful New High Pressure Pump Speeds Up 
Virus Filtration and Concentration Process
2/13/2019
Goodwin Biotechnology Inc. (GBI) is a US-based, GMP contract development and manufacturing organization (CDMO) that offers cell line development, process development, cGMP contract manufacturing, and aseptic fill/finish of mammalian cell-culture derived monoclonal antibodies, recombinant proteins, vaccines, and antibody drug conjugates (ADCs) for early- and late-stage clinical trials.
-
Goodwin Biotechnology, Inc. Release: Finding Solutions That Help A Unique Monoclonal Antibody Advance The Fight Against Metastatic Breast Cancer
4/19/2017
-
Goodwin Biotechnology, Inc. Expands Its ADC Capabilities With A High Containment Suite For Development And cGMP Manufacturing Of Cytotoxic ADCs
5/18/2016
-
IBC Generium Selects Goodwin Biotechnology, Inc. To Optimize The Process, Scale-Up, And Manufacture An Igg-Based Bispecific Antibody For Phase I Clinical Trials
4/28/2016
-
Goodwin Biotechnology, Inc. Teams With Panacea Pharmaceuticals, Inc. In Overcoming A Significant Bioconjugation Challenge For An Anti-Cancer Monoclonal Antibody
2/1/2016
-
Goodwin Biotechnology, Inc. Announces The Completion Of cGMP Manufacturing Of An IgM Monoclonal Antibody And IgM : Ligand Conjugate For Q Therapeutics, Inc., And Successful Clearance Of Q Therapeutics' IND Submission For Q-Cells Cell Therapy In ALS
7/13/2015
-
Goodwin Biotechnology, Inc. And Aspyrian Therapeutics Collaborate On The Successful GMP Manufacturing And IND Submission For A Novel Antibody Drug Conjugate (ADC) Platform
6/9/2015
-
Goodwin Biotechnology, Inc. Was Selected By Panacea Pharmaceuticals, Inc. For A Highly Specialized Vaccine Fill / Finish Project
5/11/2015
-
Goodwin Biotechnology, Inc. And Transporin Announce A Technology Collaboration That Enhances The Ability Of Antibody Drug Conjugates To Target And Deliver Payloads Into Diseased Cells
1/28/2015
-
Goodwin Biotechnology, Inc. Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
9/12/2013
-
Goodwin Biotechnology, Inc. Announces Process Development Sub-Contract for an Anthrax Vaccine
6/3/2013
-
Goodwin Biotechnology, Inc. and Coldstream Laboratories Inc. Announce a Collaboration to Develop and Manufacture Cytotoxic Antibody Drug Conjugates
4/25/2013
-
Goodwin Biotechnology, Inc. is a Three-Category Winner in the 2012 CMO Leadership Awards
10/26/2012
-
Goodwin Biotechnology, Inc. and MD Anderson Cancer Center Collaborate on the GMP Manufacturing of a Fusion Protein Conjugate that Potentially Represents a Critical Advance in Oncology
6/4/2012
-
Goodwin Biotechnology, Inc. and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology
1/3/2012
-
Goodwin Biotechnology, Inc. Announces a Collaboration with Spectros
10/24/2011
-
Goodwin Biotechnology, Inc. Announces a Collaboration With Alethia BioTherapeutics, Inc.
6/2/2011
-
Goodwin Biotechnology, Inc. and RAFAGEN Announce a Collaboration
5/18/2011
-
Goodwin Biotechnology, Inc. Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
10/18/2010
-
Goodwin Biotechnology, Inc. and Hyprocell LLC Announce Collaboration
4/28/2010